Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02773030 · OUTCOME

Progression Free Survival

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · Source last updated 2026-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
Full Range
Time frame
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks

What was measured

Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.

Analysis population: Safety Population - As per protocol, DOR and PFS will combine arms in the cohort for endpoint presentation

Groups in this outcome

Cohort A: Total

CC220

Cohort B: Total

CC220 + DEX

Cohort D: Total

CC220

Cohort E: Total

CC220 + DARA + DEX

Cohort F: Total

CC220 + BORT + DEX

Cohort G: Total

CC220 + CFZ + DEX

Cohort H1

CC220 + DEX

Cohort H2

CC220 + DEX

Cohort I

CC220 + DEX

Cohort J: Total

CC220 + NE-ASCT

Cohort K

CC220 + DARA + DEX

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A: Total29
Cohort B: Total90
Cohort D: Total107
Cohort E: Total50
Cohort F: Total29
Cohort G: Total16
Cohort H16
Cohort H25
Cohort I41
Cohort J: Total18
Cohort K75

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Cohort A: Total12.29Not reported0.1395.0Not reported
Cohort B: Total14.71Not reported0.1247.0Not reported
Cohort D: Total12.14Not reported0.1150.1Not reported
Cohort E: Total20.71Not reported2.1269.1Not reported
Cohort F: Total15.14Not reported0.1258.1Not reported
Cohort G: Total48.57Not reported4.1246.3Not reported
Cohort H126.14Not reported5.3213.1Not reported
Cohort H222.14Not reported8.346.7Not reported
Cohort I10.14Not reported0.184.4Not reported
Cohort J: Total107.00Not reported0.1127.9Not reported
Cohort K57.14Not reported0.181.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.1
        upper Limit
        395.0
        value
        12.29
      2. group Id
        OG001
        lower Limit
        0.1
        upper Limit
        247.0
        value
        14.71
      3. group Id
        OG002
        lower Limit
        0.1
        upper Limit
        150.1
        value
        12.14
      4. group Id
        OG003
        lower Limit
        2.1
        upper Limit
        269.1
        value
        20.71
      5. group Id
        OG004
        lower Limit
        0.1
        upper Limit
        258.1
        value
        15.14
      6. group Id
        OG005
        lower Limit
        4.1
        upper Limit
        246.3
        value
        48.57
      7. group Id
        OG006
        lower Limit
        5.3
        upper Limit
        213.1
        value
        26.14
      8. group Id
        OG007
        lower Limit
        8.3
        upper Limit
        46.7
        value
        22.14
      9. group Id
        OG008
        lower Limit
        0.1
        upper Limit
        84.4
        value
        10.14
      10. group Id
        OG009
        lower Limit
        0.1
        upper Limit
        127.9
        value
        107.00
      11. group Id
        OG010
        lower Limit
        0.1
        upper Limit
        81.3
        value
        57.14
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    2. group Id
      OG001
      value
      90
    3. group Id
      OG002
      value
      107
    4. group Id
      OG003
      value
      50
    5. group Id
      OG004
      value
      29
    6. group Id
      OG005
      value
      16
    7. group Id
      OG006
      value
      6
    8. group Id
      OG007
      value
      5
    9. group Id
      OG008
      value
      41
    10. group Id
      OG009
      value
      18
    11. group Id
      OG010
      value
      75
    units
    Participants
description
Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first Data will be collected and analyzed per Cohort Totals.
dispersion Type
Full Range
groups
  1. description
    CC220
    id
    OG000
    title
    Cohort A: Total
  2. description
    CC220 + DEX
    id
    OG001
    title
    Cohort B: Total
  3. description
    CC220
    id
    OG002
    title
    Cohort D: Total
  4. description
    CC220 + DARA + DEX
    id
    OG003
    title
    Cohort E: Total
  5. description
    CC220 + BORT + DEX
    id
    OG004
    title
    Cohort F: Total
  6. description
    CC220 + CFZ + DEX
    id
    OG005
    title
    Cohort G: Total
  7. description
    CC220 + DEX
    id
    OG006
    title
    Cohort H1
  8. description
    CC220 + DEX
    id
    OG007
    title
    Cohort H2
  9. description
    CC220 + DEX
    id
    OG008
    title
    Cohort I
  10. description
    CC220 + NE-ASCT
    id
    OG009
    title
    Cohort J: Total
  11. description
    CC220 + DARA + DEX
    id
    OG010
    title
    Cohort K
param Type
MEDIAN
population Description
Safety Population - As per protocol, DOR and PFS will combine arms in the cohort for endpoint presentation
reporting Status
POSTED
time Frame
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
title
Progression Free Survival
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice